April 25, 2022 5:11pm
A safe harbor was found as value was added to the lost
Pre-open indications: 2 HITs, 1 MISS and 1 Pimp/Pump/Promote
What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read facts supported by real numbers?
If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.
The Dow closed UP +240.63 points (+0.71%); the S&P closed UP +24.65 points (+0.58%) while the Nasdaq closed UP +165.56 points (+1.29%)
Henry’omics:
Indexes turned positive in in afternoon trading Monday but, market conditions remain challenging after the Dow cut a 488 point intraday loss
The Nasdaq is down approximately -10% for the month, while the Nasdaq has tumbled 19% this year.
Key market loss generator with 160 companies is expected to report earnings this week; our universe begins next week.
Volume rose sharply hitting its highest level since mid-March on the Nasdaq compared with the same time on Friday.
52-week low:
- bluebird bio (BLUE) at $3.85,
- AVROBIO (AVRO) at $1.03
- Homology Medicine (FIXX) at $1.75,
RegMed Investors’ (RMi) pre-open: “RegMed Investors’ (RMi) pre-open: a session of chance following a global sell-off.” … https://www.regmedinvestors.com/articles/12403
RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …
- Monday opened negative at 12 up/20 downs and 3 flats, flipped positive at 10:30 a.m. at 24/10 and 1 flat, the mid-day continued positive at 10/24 and 1 flat, ending with a positive close of 27/7 and 1 flat,
- Friday opened positive at 18 up/15 downs and 2 flats, flipped negative at the mid-day at 6/29, ending with a negative close of 10/23 and 2 flats,
Pre-open Indications: 2 HITs < AxoGen (AXGN +$0.09), Editas Medicine (EDIT +$0.40)> 1 MISS < CRISPR Therapeutics (CRSP +$1.59)> and 1 Pimp/Pump/Promote < Biostage (BSTG +$0.05 with 1,2273 shares traded – notice the share count?>
Key Metrics:
- Monday - Sector volume was LOW with 2 of the 27-upside having higher than the 3-month average volume with LOW volume of 2 of 7-downside having higher than the 3-month average volume;
- Friday - Sector volume was LOW with 3 of the 10-upside having higher than the 3-month average volume with LOW volume of 4 of 23-downside having higher than the 3-month average volume;
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Monday, the IBB was up +0.93% and the XBI was up +2.23%
- Friday, the IBB was down -2.32% and the XBI was down -1.59%
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Monday was down -1.19 points or -4.22% at 27.02
- Friday was up +5.27 points or +23.74% at 27.95
Jumping with share pricing momentum (10 of 27):
- Intellia Therapeutics (NTLA +$2.93 after Friday’s +$0.15),
- Beam Therapeutics (BEAM +$2.09 after Friday’s -$1.67),
- CRISPR Therapeutics (CRSP +$1.59 after Friday’s +$0.15),
- Global Blood Therapeutics (GBT +$1.50 after Friday’s -$1.27),
- BioLife Solutions (BLFS +$1.20 after Friday’s -$0.89),
- Fate Therapeutics (FATE +$0.82 after Friday’s +$0.11),
- Ionis Pharmaceuticals (IONS +$0.61 after Friday’s -$1.27),
- Ultragenyx (RARE +$0.60),
- Editas Medicine (EDIT +$0.40 after Friday’s +$0.22),
- Chinook Therapeutics (KDNY +$0.38 after Friday’s -$0.26),
Hammered in today’s market (7 of 7):
- Alnylam Pharmaceuticals (ALNY -$4.93 after Friday’s -$1.75),
- Regenxbio (RGNX -$0.17 after Friday’s -$0.23),
- Applied Genetic Technologies (AGTC -$0.031),
- Precigen (PGEN -$0.01 after Friday’s +$0.12),
- Pluristem (PSTI -$0.01),
April, Q2/2022:
- Monday closed positive with 27 incliners, 7 decliners and 1 flat
- Friday closed negative with 10 incliners, 23 decliners and 2 flats
The BOTTOM LINE: The cell and gene therapy sector took a BIG jump after Friday’s dive following market risk fears caused stocks to swoon.
“This week may easily be a fork in the road of equities. ... Bottom-up drivers will either confirm or reject what the challenging macro backdrop has given us over the last three weeks,” MKM’s JC O’Hara said in a note. <CNBC>
There are some winners of the reset: gene editing equities after having a rough time since the Broad Institute patent award as the “other” companies face negotiating licenses.
State the obvious, investors are NOT in control of daily market driven sector appreciation or downward dives.
I try to keep it simple … I don't think we've seen the bottom yet. We haven't had that big sell off yet where we have huge volumes.
We are getting close to Q2 reporting season … yet, I can’t write away my misgivings about the daily sessions.
Earnings’ season is upon us as Solid Biosciences (SLDB) reports 4/27 followed by Alnylam Pharmaceuticals (ALNY) reports Thursday,4/28 followed by Sage Therapeutics (SAGE) on 5/3 and AxoGen (AXGN), Ionis Pharmaceuticals (IONS), MiMedx (MDXG) and Vericel (VCEL), and Fate Therapeutics (FATE) on 5/4 so far.
Volume again was also barely there … as earnings might get even more ugly.
Don’t hold your breath after a few up sessions, algorithms are lurking under the surface of minimal sentiment
I stick to my view of anticipating the risks – as my careers focus has been “warning analysis”.
Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations? What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
